You Are Invited to a Complimentary CME Dinner Meeting
Introduction
Neurologists who manage Parkinson’s disease (PD) seek breakthroughs that focus on the urgent need to diagnose and treat PD as early as possible. Discoveries of disease-specific biomarkers, enhanced imaging techniques, and a thorough understanding of premotor symptoms that precede the disease will help them identify PD patients years before motor symptoms manifest. If patients are diagnosed earlier, neuroprotective therapies utilized in the beginning stages of PD will shift neurologists’ management paradigm from addressing symptoms to altering PD’s pathologic progression.The search for these therapies has been arduous, and no agents have received regulatory approval for an indication of neuroprotection. Imprecise study characteristics have made it difficult to interpret whether positive results are due to symptomatic benefits or actual neuroprotective effects. Nevertheless, recent clinical trials with more clear-cut end points may present evidence that certain neuroprotective therapies are efficacious. If results are positive, the long-awaited paradigm shift to disease modification is close to becoming reality.
There is a critical need for neurologists who manage PD to understand the significance of these breakthroughs. This interactive dinner meeting will present data from trials on neuroprotective therapies and early diagnosis, then offer expert interpretation of study results. Furthermore, attendees will have opportunities to question thought leaders on the clinical ramifications of recent research.
Target Audience
This activity is designed for physicians, physician assistants, nurse practitioners, and nurses who care for patients with PD. This activity will consist of a lecture with a guidebook as well as a question-and-answer session.Due to the clinical content of this activity, no guests may accompany the health care professional to this program.